Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riliprubart - Sanofi

Next Previous
Drug Profile

Riliprubart - Sanofi

Alternative Names: BIVV-020; SAR-445088; TNT-020

Latest Information Update: 14 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; Sanofi; Sanofi-Aventis Recherche & Developpement
  • Class Anti-inflammatories; Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection; Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Discontinued Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura; Renal transplant rejection

Most Recent Events

  • 14 Aug 2026 Discontinued - Phase-II for Idiopathic thrombocytopenic purpura (Treatment-experienced) in Czech Republic, United Kingdom, Spain, Netherlands, Germany (IV) prior to August 2026 (Sanofi pipeline, August 2026)
  • 14 Aug 2026 Discontinued - Phase-II for Renal transplant rejection (Prevention) in USA, Canada, France, Germany, Italy, Sweden, Spain (IV) prior to August 2026 (Sanofi pipeline, August 2026)
  • 14 Aug 2026 Discontinued - Phase-II for Renal transplant rejection in Canada, France, Germany, Italy, Spain, Sweden, USA (IV) prior to August 2026 (Sanofi pipeline, August 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top